The announcement made at the same time with the launch of the 2020 strategy. Sanofi has carefully analyzed all the available options regarding the future of the strategy of the generic division in Europe and decided to start the separation process.

„The generics activity remains an important one for Sanofi in other parts of the world, continuing to consolidate the contribution in this domain in the emergent markets”, says Emmanuelle Valentin, the president of the Administration Council of Zentiva. (source: business-review.eu)